Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography

NCT04338165 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Atherosclerotic Cardiovascular Disease

Interventions

DRUG: Evolocumab 140 MG/ML [Repatha]

Sponsor

University Hospital, Grenoble